As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit
Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
TODAY: Gb Sciences’ President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm’s sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson’s disease symptoms
TODAY: Gb Sciences Describes Drug Development Progress in Pharma’s Almanac Journal Article
Gb Sciences is focusing considerable resources on bringing its lead Parkinson’s disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform’s utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences’ future successes.
Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™